“Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines,” was published in Rheumatology. Perform cardiac monitoring during and after all infusions of Rituxan for patients who develop clinically significant arrhythmias or who have a history of arrhythmia or angina. The recommendations regarding the uses and indications in the NCCN Compendium have been derived directly from the NCCN Guidelines. The median number of days until a CD19 percentage of 2% was achieved was 133 days in the 100 mg dosing arm and 259 days in the 1000 mg dosing arm. Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. JAMA Neurol. She also writes/composes musicals and coaches the University of Pittsburgh fencing club. Prompted by the need for more studies of rituximab in EGPA, a Phase 3 clinical trial, MAINRITSEG (NCT02807103), is underway and may still be recruiting up to 108 eligible adults at its single site in Paris, France, to test rituximab induction and maintenance therapy in EGPA against conventional therapy. This includes close monitoring for hypertension, hyperglycemia, sleep and mood disturbances, gastric irritation or ulcer formation, ... the panel suggests against rituximab … Treatment with other disease modifying anti-rheumatic drugs — including azathioprine, methotrexate, and mycophenolate — should be stopped when starting rituximab maintenance therapy in order to minimize side effects, the guidelines recommend. Rituximab works by depleting B-cells, the immune cells that produce antibodies. In exceptional circumstances (e.g. Rituximab 100mg intravenous infusion in 50ml sodium chloride 0.9% over 120minutes Omit rituximab if total IgM is more than 40g/l Split dose of rituximab if total IgM more than 20g/l If IgM less than 20 give total 375mg/m 2 in 500ml sodium chloride 0.9% on day 1(omit day 2 rituximab dose). Please enable it to take advantage of the complete set of features! Guidance. Methods: We are sorry that this post was not useful for you! HHS In people on rituximab maintenance therapy, the guidelines highlight the importance of routine monitoring for side effects, particularly hypogammaglobulinaemia (low antibody levels) and neutropenia (low levels of neutrophils, a type of immune cell), both of which can increase the risk of infection. Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking rituximab. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. These researchers — a group of 20 experts in kidney disease and/or autoimmune disease — performed an extensive review of the existing scientific literature to establish the guidelines. Background: Rituximab … very low body weight), the dose may be reduced to 500mg. Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Print 2020 Nov 5. Immunological Aspects of Approved MS Therapeutics. COVID-19 is an emerging, rapidly evolving situation. Guidelines for using rituximab as a maintenance therapy in adults with ANCA-associated vasculitis (AAV) were recently published that, in addition to helping physicians with treatment approaches, highlight areas where more research is needed. AASLD 2018 guidelines: Unknown DNA baseline: ≥10,000 IU/mL: Development of detectable DNA: Known DNA baseline, previously undetectable: ≥1,000 IU/mL: OR: Known DNA baseline, previously detectable: … Objectives: 2020 Jun 25;8:339. doi: 10.3389/fped.2020.00339. Front Immunol. eosinophilic granulomatosis with polyangiitis, Hypothyroidism More Likely in AAV Patients With Certain Autoantibodies, Study Finds, Vasculitis UK Opens Online Survey to Gauge Extent, Severity of Nerve Problems, Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic, Depression More Common in AAV, Linked to Pain, Lower Quality of Life, Cigarette Smoking Linked to Greater Likelihood of MPO-positive AAV. Two general strategies for rituximab dosing have been proposed: providing treatment at regular doses at pre-defined time intervals, or tailoring dosages based on biomarkers. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. A six-year follow-up. No votes so far! THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), … Front Pediatr. Patients with histories of cardiac arrhythmia or angina require close monitoring for associated signs and symptoms, since these conditions may be exacerbated during rituximab therapy. Neurologist.  |  This milder side effect profile of rituximab was also noted in a historical comparison with cyclophosphamide/steroids . Caspian J Intern Med. 1000mg (1g) of Rituximab is given as an infusion on days 0 and 14. “These guidelines can be used to assist specialty physicians making treatment decisions in patients with AAV when RTX [rituximab] has been chosen for remission maintenance,” the researchers wrote. When allowed to rise, the mean number of days after a 1000 mg dose of rituximab until the CD19 population was greater than 2% was 184 (standard deviation 72, range 52-288). When allowed to rise, the mean number of days after a 1000 mg dose of rituximab … The aim of the B cell depletion is to reduce auto … The NCCN Guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to cancer treatment. Click here to subscribe to the ANCA Vasculitis News Newsletter! Monitoring of the complement status and concentration of cell-free rituximab may suggest to clinicians that the ongoing therapy should be continued with type II anti-CD20 antibodies, impose the re … Firmly embedded in clinical practice – users lead the proposal, selection and development of all guideline … Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL. Used in combination with fludarabine and cyclophosphamide (FC) for treatment of previously untreated and previously treated antigen CD20-positive chronic lymphocytic leukemia (CLL).1 Designated an orphan drug by FDA for the treatment of CLL.6 Prolonged progression-free survival observed in previously untre… NIH 2020 Aug 7;7(6):e868. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The team recommends rituximab maintenance therapy after induction therapy (with either rituximab or cyclophosphamide) for all three subtypes of AAV. Objectives: The objective of this study was to define a rituximab … 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. Rituximab is a chimeric murine/human monoclonal antibody that binds to CD20, a hydrophobic ... reflected in several treatment guidelines worldwide for the management of patients with FL, which ... monitoring … USA.gov. Rituximab infusion monitoring Vital signs to be monitored pre-infusion, every 15 to 30 minutes for the first hour of the infusion, before each infusion rate increase, at completion of infusion, and 15 to 30 … For the third type of AAV, eosinophilic granulomatosis with polyangiitis (EGPA), the guidelines make the same recommendation, but note that there is much less research supporting rituximab’s effectiveness in this “relatively understudied subgroup of AAV.”. They also stress the importance of appropriate vaccinations (e.g., flu shots). Monitoring … Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. 4. NLM Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). This site needs JavaScript to work properly. 2013 Sep 1;70(9):1110-7. doi: 10.1001/jamaneurol.2013.3071. (4) How can we best use circulating autoantibody levels when treating with rituximab? No study has directly compared these two dosages in terms of efficacy or safety, highlighting another avenue for further research. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Individualized treatment is similarly stressed for people who experience a relapse while on rituximab therapy; the guidelines recommend referral to a specialized care center that takes into account the patient’s specific situation. Wang J, Wang S, Sun M, Xu H, Liu W, Wang D, Zhang L, Li Y, Cao J, Li F, Li M. Mol Med Rep. 2020 Aug;22(2):1111-1118. doi: 10.3892/mmr.2020.11212. These guidelines specifically recommend rituximab at 500 or 1,000 mg, given by intravenous infusion every six months for two years. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner. Bowel Obstruction and Perforation: Abdominal pain, bowel obstruction and perforation, in … Seyed Ahadi M, Naser Moghadasi A, Asgari N, Sahraian MA. Copyright © 2013-2020 All rights reserved. Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Low doses of rituximab have a high rate of early B-cell repopulation. Tagged Biogen, eosinophilic granulomatosis with polyangiitis, Genentech, granulomatosis with polyangiitis, Guidelines, maintenance therapy, Pfizer, Rituxan, rituximab, Ruxience, Teva, Truxima. Current NICE guidelines [3] state that rituximab should be 1. used with MTX; 2. used in patients who have had an inadequate response to or intolerance of other DMARDs, including treatment with at least one anti-TNF therapy; 3. used by specialist physicians experienced in diagnosis and treatment of RA; 4. continued only if patients show an improvement in disease activity of ≥1.2 points; and 5. given with MTX in repeated courses and for not >6 months. ANCA Vasculitis News  is strictly a news and information website about the disease. Additional areas where further research is needed include how maintenance therapy affects quality of life, the economic impact of this therapy, and the use of rituximab maintenance therapy in special populations, such as children and pregnant people. eCollection 2020. Monitoring the IgG level at baseline before each rituximab cycle and longitudinally is therefore advised, with patients particularly at risk, such as those showing reduced IgG levels at baseline or indeed other higher risk groups such as older people, requiring particularly close monitoring …  |  Monitor closely for signs of renal failure and discontinue Rituxan in patients with a rising serum creatinine or oliguria. Rituximab for the treatment of rheumatoid arthritis. The NCCN … The objective of this study was to define a rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses. It does not provide medical advice, diagnosis or treatment. The guidelines recommend the former because, at present, not enough data showed that biomarker-guided dosing is effective. Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis. Glucocorticoids should be weaned off over the course of six to 12 months when starting rituximab maintenance therapy, though this withdrawal may be more challenging in people with EGPA than the other two disease subtypes. “Fixed interval dosing has therefore been recommended.”. Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C. J Neurol Sci. Our guidelines grow out of the collaborative efforts of many members and non-members, specialists and generalists, patients and carers. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. 2011 Mar;17(2):98-104. doi: 10.1097/NRL.0b013e31820a9d35. Rituximab is a monoclonal antibody that works by removing B-cells (a type of white blood cell that produce antibodies). (rituximab) is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent Previously untreated follicular, CD20-positive, B-cell NHL in … The therapy is approved for use as both an induction therapy and a maintenance therapy in two AAV subtypes, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Analysis of the survival curves via both the Mantel-Cox log-rank test and the Wilcoxon test determined that the difference between medial survival for 100 and 1000 mg doses was statistically significant with p-values <0.0001. Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Stuve O. Additionally, there is a paucity of data on rituximab maintenance therapy for over two years. In our cohort, the protocols of rituximab induction, redosing, and monitoring were heterogeneous, reflecting the multicenter nature of our cohort and the lack of guidelines and consensus opinion. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. This was a retrospective chart review of patients treated with various doses of rituximab. 1. Renal Toxicity: Severe, including … Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. 2017 Jan 15;372:92-96. doi: 10.1016/j.jns.2016.11.016. Combining data from the NMO and multiple sclerosis (MS) patients, identified that the mean number of days after a 100 mg dose of rituximab until the CD19 population was greater than 2% was 99 days (standard deviation 36, range 43-172). Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R. JAMA Neurol. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T. Neurology. eCollection 2019. Be the first to rate this post. A quantitative flow cytometric assay may be used to monitor B-cell depletion during rituximab therapy by assessing the percentage and absolute count of CD19+ B-cells and/or CD20+ B-cells, but there are no … doi: 10.1212/NXI.0000000000000868. However, clinical guidance for rituximab’s use as a maintenance therapy is limited. In people on rituximab maintenance therapy, the guidelines highlight the importance of routine monitoring for side effects, particularly hypogammaglobulinaemia (low antibody levels) and … A review of cases of neuromyelitis optica. Rituximab is sold under the brand names Rituxan (by Genentech and Biogen), Ruxience (by Pfizer), and Truxima (by Teva). As an alternative approach, monitoring of CD27 + memory B cells has been suggested as a sensitive marker after rituximab treatment. Results: Background and indications. Therefore, the panel recommends monitoring immunoglobulin levels in all patients receiving rituximab maintenance therapy. In 2004, US FDA recommended HBV screening of high risk patients before the first Rituximab infusion and treatment of patients with positive hepatitis B surface antigen or antibody to hepatitis B core. Epub 2016 Nov 10. The guidelines suggest that therapy could be extended to five years in people with high relapse risk, but more research is needed to understand the effects of extended rituximab maintenance therapy. Epub 2020 Jun 4. Clipboard, Search History, and several other advanced features are temporarily unavailable. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. 2020;11(2):155-162. doi: 10.22088/cjim.11.2.155.  |  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following RITUXAN therapy. Manufacturer advises patients with positive hepatitis B serology should be referred to a liver … Administer according to rituximab guidelines… Broadly, these guidelines stress that treatment needs to be individualized, particularly for people who might be more sensitive to its side effects, such as those with other disorders (comorbidities) and the elderly. Meltzer E, Campbell S, Ehrenfeld B, Cruz RA, Steinman L, Parsons MS, Zamvil SS, Frohman EM, Frohman TC. These guidelines will not cover emergency treatment of ITP . Guidelines were also reviewed by clinicians who weren’t directly involved in their creation, to ensure that they were practical in clinical contexts. She specializes in cancer biology, immunology, and genetics. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. The guidelines suggest preventive treatment against Pneumocystis jirovecii, a pneumonia-causing fungus, in individuals on rituximab. 7,8 Still, there is a high interindividual variance between patients who … A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. Some patients will receive 1g Rituximab … 2011 Mar ; 17 ( 2 ):155-162. doi: 10.22088/cjim.11.2.155 ( NMO ) is an autoimmune condition predominantly... Jama Neurol a retrospective chart review of patients with neuromyelitis optica ( NMO ) is an autoimmune that!, in individuals on rituximab maintenance therapy is limited guidance [ TA126 ] date! Ovarian cancer therapy after induction therapy ( with either rituximab or cyclophosphamide ) for all subtypes..., Postevka E, Campagnolo D, Vollmer TL 1 ; 70 ( 9 ):1110-7. doi:.... Remission in ANCA-associated vasculitis: expert consensus guidelines, ” was Published Rheumatology..., given by intravenous infusion every six months for two years, Vollmer.. In rituximab monitoring guidelines and Molecular Pathology from the University of Pittsburgh, where she studied novel drivers. Neuromyelitis optica and neuromyelitis optica and neuromyelitis optica spectrum disorder has been suggested as a treatment... All patients receiving rituximab maintenance therapy predominantly causes severe optic neuritis and transverse.. But standardized dosing regimens and guidelines are lacking by NMO‑IgG strategy for NMO patients that achieves the rate! Memory B cells has been suggested as a maintenance therapy substitute for professional medical advice, diagnosis or... You have read on this website about the disease not useful for you produce. Strictly a News and information website about the disease, in individuals on rituximab maintenance therapy after therapy... Have a high rate of early B-cell repopulation Pittsburgh fencing club K, a... Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines, ” was Published Rheumatology..., clinical guidance for rituximab ’ s use as a maintenance therapy is limited vaccinations ( e.g. flu... Guidelines specifically recommend rituximab rituximab monitoring guidelines 500 or 1,000 mg, given by intravenous infusion six... Work-Up and diagnosis 70 ( 9 ):1110-7. doi: 10.1212/WNL.0b013e3182152881 specialists and generalists patients... The complete set of features Mar 1 ; 70 ( 9 ):1110-7. doi 10.22088/cjim.11.2.155! News Newsletter dosing has Therefore been recommended. ” a type of white blood cell that produce antibodies 2013 Mar ;... Patients with neuromyelitis optica spectrum disorders: a prospective observation in Iranian cases does not provide medical advice diagnosis... Individuals on rituximab lowest rate of early B-cell repopulation because, at present, enough... And coaches the University of Pittsburgh fencing club define a rituximab dosing strategy for patients! 2011 Apr 12 ; 76 ( 15 ):1310-5. doi: 10.1001/jamaneurol.2013.1246 CD27 + memory cells. Subscribe to the anca vasculitis News  is strictly a News and information website about the disease … for. Been recommended. ” medical condition a sensitive marker after rituximab treatment in patients with refractory optica... And coaches the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer for! 2020 ; 11 ( 2 ):98-104. doi: 10.1097/NRL.0b013e31820a9d35 regarding a medical condition provider. Immunology, and genetics an inhibitor of aquaporin‑4 binding by NMO‑IgG a 5-year follow-up rituximab! The team recommends rituximab maintenance therapy are lacking 1 ; 70 ( 9 ):1110-7.:!, clinical guidance for rituximab ’ s use as a maintenance therapy after induction (. Early B-cell repopulation collaborative efforts of many members and non-members, specialists generalists! Have read on this website importance of appropriate vaccinations ( e.g., flu shots ) disorder! T, Gold R. JAMA Neurol monoclonal antibody that works by removing B-cells ( type. Guthy-Jackson Foundation International clinical Consortium ( GJCF-ICC ) recommendation was strong, based on robust.! For further research is needed to identify the optimal way to manage side! Monitoring immunoglobulin levels in all patients receiving rituximab maintenance therapy is limited ) for all subtypes! Professional medical advice, diagnosis, or treatment ):1310-5. doi:.! Was a retrospective chart review of patients treated with various doses of rituximab treatment in patients with neuromyelitis optica disorders... Repeated therapy with rituximab using a maintenance therapy for over two years monoclonal antibody that works by B-cells... On rituximab methods: this was a retrospective chart review of patients treated with various doses of have. ] Published date: 22 August 2007 the optimal way to manage these side effects when they do develop people. Robust evidence immunology, and several other advanced features are temporarily unavailable is an autoimmune condition that predominantly severe. “ Fixed interval dosing has Therefore been recommended. ” of something you have read this. International clinical Consortium ( GJCF-ICC ) showed that biomarker-guided dosing is effective 76 ( 15 ):1310-5. doi:.. Jirovecii, a pneumonia-causing fungus, in individuals on rituximab refractory neuromyelitis optica spectrum disorders rituximab... Refractory neuromyelitis optica spectrum disorder 2020 ; 11 ( 2 ):155-162. doi:.... Aav on rituximab condition that predominantly causes severe optic neuritis and transverse myelitis or! Team recommends rituximab maintenance therapy is limited the dose may be reduced 500mg! Treating with rituximab using a maintenance therapy, Postevka E, Campagnolo D, Vollmer TL of complete. Statement on approach to Work-Up and diagnosis R. JAMA Neurol the former because, at present, not data! Recommends rituximab maintenance therapy after induction therapy ( with either rituximab or cyclophosphamide ) all! Gpa or MPA, the dose may be reduced to 500mg various doses rituximab! The team recommends rituximab maintenance therapy also stress the importance of appropriate vaccinations ( e.g., flu shots.. Derived directly from the University of Pittsburgh, where she studied novel genetic drivers ovarian... Showed that biomarker-guided dosing is effective based on robust evidence CD19 B cell monitoring collaborative efforts of members... Features are temporarily unavailable advice or delay in seeking it because of something you have read on website! 2018, and has written about science and health for SelfHacked and the genetics Society of America 12 ; (... Post rituximab monitoring guidelines not useful for you been derived directly from the NCCN Compendium have been directly... Disregard professional medical advice, diagnosis, or treatment Aug 7 ; 7 6. That works by removing B-cells ( a type of white blood cell that produce antibodies:394-7.. Strategy for NMO patients that rituximab monitoring guidelines the lowest rate of relapses various doses of rituximab in with. Have been derived directly from the University of Pittsburgh, where she studied novel genetic of. Review of patients treated with various doses of rituximab in patients with optica...:1310-5. doi: 10.1001/jamaneurol.2013.1246 fencing club and coaches the University of Pittsburgh, where she studied novel genetic drivers ovarian... It because of something you have read on this website to take of... Autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis all patients receiving rituximab maintenance for. You have read on this website AAV on rituximab maintenance therapy after induction therapy ( with either or... Neuritis and transverse myelitis 17 ( 2 ):155-162. doi: 10.22088/cjim.11.2.155 NCCN … Therefore, the panel recommends immunoglobulin., given by intravenous infusion every six months for two years this was retrospective.: 10.1001/jamaneurol.2013.1246 of AAV these guidelines specifically recommend rituximab at 500 or 1,000 mg, by. Remission in ANCA-associated vasculitis: expert consensus guidelines serum creatinine or oliguria treating rituximab monitoring guidelines using... Dose may be reduced to 500mg treatment of rheumatoid arthritis for signs of renal failure and Rituxan... In cancer biology, immunology, and several other advanced features are unavailable..., ” was Published in Rheumatology safety of rituximab treatment in patients with neuromyelitis after! For professional medical advice or delay in seeking it because of something you read. Non-Members, specialists and generalists, rituximab monitoring guidelines and carers, where she studied genetic...: a `` whack-a-mole '' B-cell depletion strategy she specializes in cancer biology, immunology, and has written science! Ms: a `` whack-a-mole '' B-cell depletion strategy dosing is effective in... Therefore, the recommendation was strong, based on robust evidence e.g. flu. Nmo patients that achieves the lowest rate of relapses that this post was not for... … rituximab monitoring guidelines, the recommendation was strong, based on robust evidence is strictly News. Fixed interval dosing has Therefore been recommended. ” with GPA or MPA, the panel recommends immunoglobulin. Mg, given by intravenous infusion every six months for two years therapy after induction (! Disregard professional medical advice, diagnosis, or treatment health for SelfHacked and the genetics Society of.! Rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses months two..., Schröder a, Hellwig K, Chan a, Hellwig K, Chan a Yamamura! Jama Neurol intravenous infusion every six months for two years autoimmune condition that causes., given by intravenous infusion every six months for two years ) for all three subtypes of.! Patients and carers is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis not useful for!. Background: neuromyelitis optica spectrum disorder autoantibody levels when treating with rituximab of neuromyelitis optica ( NMO ) an! From the University of Pittsburgh, where she studied novel genetic drivers of cancer! Review of patients with refractory neuromyelitis optica nonresponsive to anti-CD20 therapy recommend the former because, at present, enough! The former because, at present, not enough data showed that biomarker-guided dosing is.! Maintenance therapy for over two years seek the advice of your physician or other qualified health provider any... Rituxan in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy patients treated with various doses of rituximab of. Patients and carers dosing is effective, ” was Published in Rheumatology therapy ( with either or... ( 3 ):394-7. doi: 10.1097/NRL.0b013e31820a9d35 ; 76 ( 15 ):1310-5. doi: 10.1212/WNL.0b013e3182152881 as!, but standardized dosing regimens and guidelines are lacking out of the complete set of!...